Last Price
10.40
Today's Change
0.00 (0.00%)
Day's Change
0.00 - 0.00
Trading Volume
0
Market Cap
1 Billion
Shares Outstanding
109 Million
Avg Volume
1,039,281
Avg Price (50 Days)
11.08
Avg Price (200 Days)
8.66
PE Ratio
-4.18
EPS
-2.49
Earnings Announcement
07-Nov-2024
Previous Close
10.38
Open
10.38
Day's Range
10.38 - 11.16
Year Range
3.67 - 12.61
Trading Volume
2,608,803
1 Day Change
0.19%
5 Day Change
3.38%
1 Month Change
-8.05%
3 Month Change
22.07%
6 Month Change
41.50%
Ytd Change
66.67%
1 Year Change
44.24%
3 Year Change
0.78%
5 Year Change
157.43%
10 Year Change
0.00%
Max Change
0.00%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.